Rxivist logo

TRIM21 and PHLDA3 Negatively Regulate the Cross-Talk between the PI3K/AKT Pathway and PPP Metabolism

By Jie Cheng, Yan Huang, Xiaohui Zhang, Yue Yu, Wanru Zhang, Shumin Wu, Jing Jiao, Mei Wang, Linh Tran, Liuzhen Zhang, Mengyao Wang, Wenyu Yan, Yilin Wu, Fangtao Chi, Peng Jiang, Xinxiang Zhang, Hong Wu

Posted 30 Aug 2019
bioRxiv DOI: 10.1101/750976

PI3K/AKT signaling is known to regulate cancer metabolism but whether metabolic pathway feedbacks and regulates the PI3K/AKT pathway is unclear. Here, we demonstrate the important reciprocal cross-talks between the PI3K/AKT signal and PPP branching metabolic pathways. PI3K/AKT activation stabilizes G6PD, the rate-limiting enzyme of PPP, by inhibiting a newly identified E3 ligase TIRM21, and promotes PPP. PPP metabolites, in turn, reinforce AKT activation and further promote cancer metabolic reprogramming by blocking the expression of an AKT inhibitor PHLDA3. Knockout TRIM21 or PHLDA3 promotes the cross-talks and cell proliferation. Importantly, PTEN null human cancer cells and in vivo murine models are sensitive to anti-PPP treatments, suggesting the importance of PPP in maintaining AKT activation even in the presence of a constitutively activated PI3K pathway. Our study suggests that blockade of these reciprocal cross-talks may have a therapeutic benefit for cancers with PTEN loss or PI3K/AKT activation.

Download data

  • Downloaded 325 times
  • Download rankings, all-time:
    • Site-wide: 113,752
    • In cancer biology: 3,448
  • Year to date:
    • Site-wide: 52,131
  • Since beginning of last month:
    • Site-wide: 121,637

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide